FDA Approval for TactiFlex Duo Bolsters Abbott's EP Portfolio, But Valuation and Risks Remain

What happened

Abbott Laboratories received FDA approval for its TactiFlex Duo ablation catheter on September 9, 2026, adding a dual-energy option (pulsed field ablation and radiofrequency) to its U.S. atrial fibrillation portfolio. This approval follows the CE mark in Europe and complements the earlier U.S. approval of Volt PFA, strengthening Abbott’s competitive position in the fast-growing electrophysiology market. The company’s Medical Devices segment has been a bright spot, growing 8% ex-FX in the first half of 2026 with EP up 13%, and this approval could extend that momentum in the U.S. However, Abbott’s stock already trades at 34.5 times earnings, and the approval was largely anticipated given the product’s European clearance; it does little to address persistent concerns around the Libre FDA warning letter, dilutive Exact Sciences acquisition, and declining nutrition volumes. While the news is positive for Abbott’s innovation pipeline, it is unlikely to be a major catalyst for re-rating the stock from its current level near $107.

Implication

The TactiFlex Duo approval reinforces Abbott’s ability to innovate and compete in the high-growth EP market, which supports the bull case of sustained medical-device growth above 8%. However, the device segment’s strength is already reflected in the stock’s premium valuation, and the incremental U.S. launch may take several quarters to materially impact revenue. The overhangs of the FDA warning letter at Abbott Diabetes Care, the earnings dilution from Exact Sciences through 2027, and ongoing nutrition volume declines continue to weigh on the risk-reward. A meaningful re-rating would require resolution of those issues or evidence that the new product cycle significantly accelerates segment growth beyond current expectations. Until then, the stock likely remains range-bound, with attractive entry closer to $98 and a trim level near $118.

Thesis delta

The FDA approval for TactiFlex Duo incrementally strengthens the medical-device growth pillar that underpins the bull scenario, but it does not shift the overall thesis. The core concerns—high valuation, Libre regulatory risk, Exact Sciences dilution, and nutrition weakness—remain unchanged. Therefore, the WAIT rating and price parameters from the prior report stand; the approval is a positive development but insufficient to upgrade the stock.